How Do CJC-1295 and Ipamorelin Work Together?

By  //  May 31, 2023

The topic of this article will focus on CJC-1295 and Ipamorelin peptides.

Research on both peptides has put forth some suggested hypotheses on their mechanisms of action and potential in the following cases:

  • Possibly speed up the metabolism, increase lean muscle mass, and decrease body fat
  • Possibly improve both mental and physical immunity
  • Possibly lower blood sugar levels
  • Possibly have anti-aging properties
  • Possibly increase production of collagen and elastin
  • Possibly speed up healing times, particularly for joint injuries
  • Possibly improve cognitive functioning

CJC-1295 and Ipamorelin Peptide Blend

Although organisms produce many peptides naturally, a lack of peptides in certain organisms due to genetics or environmental factors is not unusual. Even if it weren’t, the body’s amino acid levels and the speed at which normal physical operations occur are considered to naturally decline with age.

Studies suggest that energy level and muscle mass may both be affected by growth hormones. The amounts of these hormones may decrease as organisms age. Scientists posit that hormone levels decline by 14% every decade [i] after maturation. 

Research suggests Ipamorelin and CJC-1295 are two examples of synthetically produced peptides that may exhibit dramatic increases in growth hormone levels when given to animal test subjects. These peptides have been studied alone and in combination both for their performance potential.

Combining CJC-1295 with Ipamorelin

Two examples of growth hormone secretagogues are the synthetic pentapeptide Ipamorelin [ii] and the 29-amino-acid peptide CJC-1295 [iii].

Growth hormone secretagogues (GSHs) are a class of peptides that act as growth hormone release stimulators but are not themselves growth hormone-producing peptides. Ipamorelin and CJC-1295 are members of this peptide class; studies suggest they may act similarly but have somewhat different half-lives and pharmacokinetic characteristics.


In the early 1990s, Ipamorelin was first synthesized after years of constant study. Ipamorelin is the first selective, synthetic growth hormone secretagogue with suggested efficacy in vitro [v].

Synthesized GH-releasing peptides and secretagogues had a limited half-life, meaning their impact not not be long-lasting. Therefore, scientists kept digging and developing more durable peptides. The stabilizing peptide CJC 1295 [vi] was discovered using one of these methods.

What is the Purpose of CJC-1295 and Ipamorelin Peptide Blend? 

Scientists hypothesize both CJC-1295 and Ipamorelin peptides may stimulate a subset of the anterior pituitary gland, increasing circulating levels of growth hormone. Once activated, this component may secrete growth hormones spontaneously, possibly allowing a body to stabilize its supply (5).

Studies suggest CJC-1295 peptide may be more active and resistant to proteolytic enzymes thanks to structural changes involving four amino acids. Researchers speculate these alterations may permit covalent binding of the peptide to blood albumin, with some evidence suggesting that it may also bind to fibrinogen and immunoglobulin G (IgG) in very small concentrations [vi]. Growth hormone and insulin-like growth factor 1 (IGF-1) levels in the blood may subsequently increase.

Researchers speculate Ipamorelin may be the first peptide in the peptide blend to take action following presentation to the test subject. Studies suggest the properties of the CJC 1295 peptide may be seen as early as the second hour [vii] after delivery, and they intensify over the tapering-off period. 

CJC-1295 and Ipamorelin Peptide Blend Research 

CJC-1295 and Ipamorelin Peptide Blend and Growth Hormone Secretagogues

Ipamorelin and CJC-1295 are peptides considered growth hormone secretagogues, and this research aims to evaluate their potential in test subjects. In this study, subjects were given a variety of GSHs, and their physiological responses were recorded.

This extensive research suggested that supplemental GSHs appeared to have boosted subjects’ development rates, increased their appetites, and enhanced their lean body mass. The findings also suggested these peptides may have enhanced sleep quality, decreased bone turnover, and boosted lean body mass in obese subjects.


The synthetic polypeptides CJC-1295 and Ipamorelin are considered GSHs (growth hormone secretagogues).

Research suggests both peptides may act as growth hormone secretagogues (GSHs), potentially stimulating the anterior pituitary gland to produce growth hormones naturally and keeping an organism in balance.

Scientists hypothesize that Ipamorelin and CJC-1295 peptides have different half-lives and pharmacokinetics profiles. According to studies, Ipamorelin has a half-life of 2 hours, whereas CJC 1295 has a half-life of at least 8 days. 

More investigation is required to explore its potential in scientific research, and these studies must continue. Only academic and scientific institutions are allowed to use CJC-1295 and Ipamorelin peptides. If you are a licensed professional and want to buy peptides for your clinical studies, visit the Biotech Peptides website. Please note that none of the items mentioned are approved for human or animal ingestion. Laboratory research compounds are only for in-vitro and in-lab use. Any kind of physical introduction is illegal. Only authorized professionals and working scientists may make purchases. The content of this piece is intended only for educational purposes.


[i] A Giustina, JD Veldhius, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human, Endocrinology, 1 December 1998,

[ii] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.

[iii] Lucie Jette et al, hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog, ResearchGate, January 2005.

[iv] Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004

[v] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822

[vi] The Discovery of Growth Hormone-Releasing Hormone: An Update

[vii] Gobburu JV, Agersø H, Jusko WJ, Ynddal L (September 1999). “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers”. Pharmaceutical Research. 16 (9): 1412–6. doi:10.1023/A:1018955126402